PROSPECTS FOR THE CLINICAL APPLICATION OF MONOCLONAL ANTIBODIES TO IL-6 IN RHEUMATOID ARTHRITIS

Abstract

This article provides a review of olokizumab (OKZ) efficacy in 2 modes in phase III rheumatoid arthritis. Treatment with OKZ 64 mg every 2 weeks and 4 weeks was compared to placebo and adalimumab (CREDO 2) in combination with methotrexate (MTX) in populations of patients with inadequate response to MTX (CREDO 1 and CREDO 2) and to TNF inhibitors (CREDO 3). Olokizumab efficacy was confirmed in all studies. The primary endpoint of the ACR20 (American College of Rheumatology - 20) response was achieved in the comparable number of patients in OKZ and adalimumab (ADA) treatment. It was registered in 70.3% of patients receiving OKZ 2 weeks group, 71.4% of patients receiving OKZ 4 weeks group, 66.9% of patients in the ADA group and 44.4% of patients in the placebo group (p<0.0001) (CREDO2). The percentage of ACR20 response in treatment arms did not depend on gender, age, body mass index, initial RA severity, previous duration of MTX treatment, presence of antibodies to cyclic citrullinated proteins and rheumatoid factor (CREDO1, CREDO2). Positive dynamics of various efficiency indicators, including quality of life, were recorded in patients treated with OKZ. Similar results were obtained in the CREDO 3 study. At the same time, there were no signs that could have a negative impact on the evaluation of the "Benefit-risk" ratio of treatment with OKZ.